|
CN111205297A
|
|
Preparation method of forbitasvir RRRR type enantiomer
|
|
CN111303169A
|
|
Preparation method of fubitavir
|
|
CN111205298A
|
|
Preparation method of forbitasvir RRRS type isomer
|
|
CN111253376A
|
|
Preparation method of fubitasvir SRSS type isomer
|
|
CN111233686A
|
|
Method for recrystallizing levocarnitine
|
|
CN111233854A
|
|
Preparation method of pidotimod impurity
|
|
CN111233601A
|
|
Chiral resolution method of aryl halogen compound
|
|
CN111253270A
|
|
Levocarnitine desalination method
|
|
CN111362974A
|
|
Preparation method of fubitavir impurity
|
|
CN111303170A
|
|
Salt forming method of fubitasvir
|
|
CN108088936A
|
|
Prepare impurity and its quality determining method obtained by Pidotimod ethyl ester
|
|
CN108195953A
|
|
Prepare impurity and its quality determining method obtained by Pidotimod
|
|
CN109846878A
|
|
HCV-Ab IgG combination medicine
|
|
CN109846883A
|
|
Benzofuran derivatives and TMC435 combination medicine
|
|
CN109846899A
|
|
Benzofuran derivatives and GS-7977 combination medicine
|
|
CN107936007A
|
|
A kind of synthetic method of Lurasidone HCl
|
|
CN107954887A
|
|
A kind of method for preparing tranexamic acid
|
|
CN107814789A
|
|
A kind of synthetic method of his Wei initiation material of Dacca
|
|
TW201734011A
|
|
Preparation method of benzofuryl analogue and intermediate and crystal form thereof
|
|
CN105732602A
|
|
Benzofuran analogue used as NS4B inhibitor
|
